Scientific Director
Department of Rare Blood Disorders, Novo Nordisk A/S, Måløv, Denmark
Måløv, Denmark
Marianne Kjalke is Scientific Director in the department of Rare Blood Disorders, Rare Disease Research, Novo Nordisk. Marianne is responsible for in vitro biological characterization of haemostatic proteins for haemophilia and other bleeding disorders. Since 2019, Marianne has been responsible for coordinating the non-clinical scientific activities for concizumab. Besides concizumab, Marianne have been involved in designing and characterization of NovoEight and Esperoct and have contributed to understanding the mechanism of action of NovoSeven. Marianne has a MSc in Biochemistry and a PhD in protein chemistry from University of Copenhagen. In 1996 she had a sabbatical at University of North Carolina at Chapel Hill, US, where she joined the group of Dr Harold Roberts.
Sunday, June 25, 2023
18:30 – 19:30 ET
PB0168 - In vitro assessment of clinical coagulation assays in the presence of concizumab
Sunday, June 25, 2023
18:30 – 19:30 ET
OC 59.2 - Analyzing Concizumab mechanism of action by a Mathematical Modeling Approach
Tuesday, June 27, 2023
15:00 – 15:15 ET
OC 59.5 - Evaluation of Concizumab in Hemophilia Using Microfluidic Flow Assays
Tuesday, June 27, 2023
15:45 – 16:00 ET